Our Mission:

Making the business of CGT viable through G-Rex

Simplest way to produce a drug product.
Least variables to control to assure drug product quality.
World's only linearly scalable CGT technology.

FDA & EMA have sanctioned miniature G-Rex devices as a "qualified reduced scale model" as a surrogate for full-scale G-Rex clinical and commercial production

Miniature G-Rex devices enable full-scale manufacturing with least amount of time and money.

The only technology that can be used across all CGT functions:

R&D

Preclinical

Clinical

Commercial

Fully automatable with robotics

Integrated Process Analytic Technology

Non-invasive SMART sensors can determine cell quantity in-real time

Proof of technological superiority:

G-Rex is the world’s most robust commercial manufacturing platform

G-Rex is used to make five commercially approved drug products
G-Rex is used by ~50% of clinical trial sponsors in the USA

CAR-T, TCR-T, TIL, NK, HSC, Treg, yδ T cells, etc.
G-Rex is used in virtually every academic center doing CGT research & development

G-Rex has been cited in >1,000 peer-reviewed publications
Hundreds of CGT entities are using the $42M G-Rex Grant Program to advance the next generation of cell and gene-modified cell therapies
The FDA & EMA are very familiar with G-Rex through its frequent presence in IND and CTA filings and through commercial drug approvals.

The FDA also uses G-Rex to manufacture cells for their internal research programs
Wilson Wolf makes G-Rex under exceptionally strong quality and manufacturing systems without a single backorder

Wilson Wolf has never had a major audit finding despite numerous audits by CGT companies, including 22 within the last year

Wilson Wolf is not a venture backed company and has no risk of going out of business